ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.69322
0.07%
Brent Oil
83.20
-0.01%
Bitcoin
66,379.17
1.75%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Noticias

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATRA
FechaHoraFuenteTítuloSímboloCompañía
16/05/202420:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202415:30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
03/05/202415:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
28/03/202407:30Business WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
06/03/202417:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
29/02/202408:05Business WireAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyNASDAQ:ATRAAtara Biotherapeutics Inc
28/02/202415:30Business WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
14/02/202408:00Business WireAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisNASDAQ:ATRAAtara Biotherapeutics Inc
01/02/202401:25PR Newswire (US)Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet OncologyNASDAQ:ATRAAtara Biotherapeutics Inc
09/01/202415:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202408:00Business WireAtara Biotherapeutics Announces $15 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202407:00Business WireAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
04/01/202415:01Business WireAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
03/01/202415:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
20/12/202315:01Business WireAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesNASDAQ:ATRAAtara Biotherapeutics Inc
11/12/202311:00Business WireAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
01/12/202315:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
29/11/202317:05Business WireAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023NASDAQ:ATRAAtara Biotherapeutics Inc
22/11/202315:01Business WireAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/11/202315:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATRAAtara Biotherapeutics Inc
13/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATRAAtara Biotherapeutics Inc
10/11/202315:01Business WireAtara Biotherapeutics To Participate at the Stifel Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
08/11/202316:35Business WireAtara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple SclerosisNASDAQ:ATRAAtara Biotherapeutics Inc
01/11/202316:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATRAAtara Biotherapeutics Inc
01/11/202307:30Business WireAtara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial ResultsNASDAQ:ATRAAtara Biotherapeutics Inc
19/09/202315:50Dow Jones NewsAtara Biotherapeutics to Submit New FDA Biologics License Application in 2QNASDAQ:ATRAAtara Biotherapeutics Inc
19/09/202315:01Business WireAtara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on ComparabilityNASDAQ:ATRAAtara Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATRA

Su Consulta Reciente

NASDAQ
SSPKU
Silver Spike Acquisition
CSE
GWAY
Greenway Greenhouse Cann...
CSE
MMC
Myriad Metals
ASX
SKIJOF
ASX
VTIOA
Visioneering Technologies
TSXV
PALI
Palisades Goldcorp
USOTC
FFMH
First Farmers and Mercha... (PK)
CSE
SLV
Silver Dollar Resources
COIN
TKOETH
Tokocrypto Token
COIN
FTNBTC
NASDAQ
ACCP
ACCELERATED PHARMA, INC.
NASDAQ
SSBK
Southern States Bancshares
COIN
JDIIUST
JDIToken
LSE
CGOP
DOWI
DJGSHT
DJ Global Shipping Total...
BOV
R1DY34
Dr. Reddy`s Laboratories
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados